Jubilant Pharmova Limited has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company’s Board of Directors approved these results, which include both standalone and consolidated figures. Key financial statements such as the Statement of Unaudited Financial Results, Assets and Liabilities, and Cash Flows for the respective periods have been released.
Financial Results for Q2 FY27 Announced
Jubilant Pharmova Limited has officially released its unaudited financial results for the second quarter and the first half of the fiscal year 2026-27, ending on September 30, 2026. The company’s Board of Directors approved these results during their meeting held on November 13, 2026.
Standalone Financial Highlights
The standalone financial statements include the Statement of Unaudited Financial Results, detailing revenue from operations, expenses, profit before tax, and profit for the period. For the quarter ended September 30, 2026, the company reported a profit of ₹76 million from continuing operations. The Statement of Standalone Unaudited Assets and Liabilities as of September 30, 2026, shows total assets of ₹24,576 million and total equity and liabilities of ₹24,576 million. The Statement of Standalone Unaudited Cash Flows for the half-year ended September 30, 2026, indicates net cash generated from operating activities amounted to ₹339 million.
Consolidated Financial Highlights
The consolidated financial results encompass the Group’s performance, including its subsidiaries and associate. For the quarter ended September 30, 2026, consolidated profit after tax was ₹310 million. The Statement of Consolidated Unaudited Assets and Liabilities as of September 30, 2026, reported total assets of ₹166,646 million and total equity and liabilities of ₹166,646 million. The consolidated cash flow statement shows net cash generated from operating activities for the half-year ended September 30, 2026, at ₹3,802 million.
Auditor’s Review
The unaudited financial results, both standalone and consolidated, have undergone a limited review by the Statutory Auditors, Walker Chandiok & Co LLP. Their review reports confirm that, based on the review, nothing has come to their attention that causes them to believe the accompanying statements contain material misstatements or have not disclosed information as per the Listing Regulations.
Source: BSE
